The World Health Organization said on Monday it had approved Bavarian Nordic's mpox vaccine for adolescents aged 12 to 17 years, an age group considered especially vulnerable to outbreaks of the ...

The first mpox vaccine approved by the WHO is MVA-BN, made by Bavarian Nordic A/S. It was approved for emergency use and can be used "off-label" in infants, children and adolescents as well as in ...

Bavarian Nordic said on Thursday its mpox vaccine was approved by the EU's drug regulator for use in adolescents, bolstering the case for using the shot in the 12 to 17 age group to contain an ...

World Health Organization approves Bavarian Nordic's mpox vaccine, clearing the way for heightened response in Africa Topic: Vaccines and Immunity Fri 13 Sep Friday 13 September Fri 13 Sep 2024 at ...

Key takeaways: Jynneos was safe and generated an antibody response in adolescents that was similar to that seen in adults. The new data could help expand the number of people eligible for the vaccine.

Bavarian Nordic’s Mpox vaccine met with the World Health Organization's approval on Monday for use among adolescents aged between 12-17. This age bracket is considered to be highly vulnerable to ...